Skip to McMaster Navigation Skip to Site Navigation Skip to main content
McMaster logo

Hematology & Thromboembolism – Research

The Division of Hematology and Thromboembolism has an active research programme and is well-recognized for its research in thrombosis and hemostasis, platelet physiology and function, blood transfusion therapy, the molecular biology of red cell disorders and trials in malignant hematologic diseases. Members of our Division hold Endowed Chairs and Professorships, as well as Canada Research Chairs. Funding for our research comes from a variety of sources, including CIHR, the Heart and Stroke Foundation, and Canadian Blood Services. On average, division members are responsible for over 100 manuscripts per year; many of which are in leading academic journals like the New England Journal of Medicine, Lancet, Circulation, and Blood.

The Department of Medicine houses two research organizations devoted to hematology-based research. The Thrombosis and Atherosclerosis Research Institute (TaARI, directed by Dr. Jeffrey Weitz) describes its mission as “to reduce death and disability from thrombotic diseases by conducting research into the pathogenesis, prevention, diagnosis and treatment of thrombosis and vascular disease”. The McMaster Centre for Transfusion Research (directed by Dr. Donald Arnold) is “dedicated to the advancement of evidence-based diagnostic, clinical, and therapeutic practices in transfusion medicine through research, innovation, and training”. Some division members have affiliations with the Population Health Research Institute (PHRI). Much of the Division’s thrombosis research is conducted through the Canadian Venous Thromboembolism Research Network (CanVECTOR), a national patient-oriented, program centred on venous thromboembolism-related research, training, and knowledge translation.

A McMaster Division of Hematology & Thromboembolism AFP Student Research Project Competition is held annually. Three awards were provided in 2019:

  • 1st prize ($10,000): Dr. Madeleine Verhovsek (faculty), Dr. Derek Chan (trainee) for “Evaluating health resource utilization patterns in sickle cell disease in emergency departments in Ontario, Canada”.
  • 2nd prize ($5,000): Dr. Donald Arnold (faculty), Dr. Amaris Balitsky (trainee) for “Defining clinically significant bleeding as an outcome in blood transfusion trials”.
  • 3rd prize ($2,500): Dr. Mickey Zeller (faculty), Dr. Siraj Mithoowani (trainee) for “Anything but cookbook medicine – applying variation theory to understand the influence of thrombosis clinical practice variability on resident learning”.

Major Awards

  • Dr. Jeffrey Weitz: American Society of Hematology (ASH) Ernest Beutler Lecture and Prize (2019).
  • Dr. Graham Turpie: inaugural TaARI Distinguished Career Award (2019).
  • Dr. James Douketis: American College of Physicians Laureate Award (2020).

Key Grants

  • Dr. Donald Arnold: A randomized open-label trial of convalescent plasma for hospitalized adults with acute COVID-19 respiratory illness (CONCOR-1) (CIHR, $2,972,00, 2020).
  • Dr. Donald Arnold: Management of bleeding emergencies in patients with immune thrombocytopenia (CIHR, $218,025, 2019).
  • Dr. John Eikelboom: Anti-coronavirus therapy (ACT) to prevent COVID-19 disease progression: a clinical trial platform (CIHR, $2,937,000, 2020).
  • Dr. Paul Kim: COVID-19 – comprehensive biomarker analysis for prediction of clinical course and patient treatment outcomes (COVID-BEACONS) (CIHR, $1,173,000, 2020).
  • Dr. Colin Kretz: Investigating the regulation of ADAMTS13 in hemostasis and thrombosis (CIHR, $147,645, 2020).
  • Dr. Deborah Siegal (Co-Principal Investigator): Venous thrombosis virtual surveillance in COVID (VVIRTUOSO) (CIHR, $304,000, 2020).
  • Dr. Geoffrey Werstuck: Investigating the role of glycogen synthase kinase (GSK)-3 in atherosclerosis (CIHR, $255,256, 2019).

Key Publications

  • Douketis JD, Spyropoulos AC, Duncan J, Carrier M, Le Gal G, Tafur AJ, Vanassche T, Verhamme P, Shivakumar S, Gross PL, Lee AYY, Yeo E, Solymoss S, Kassis J, Le Templier G, Kowalski S, Blostein M, Shah V, MacKay E, Wu C, Clark NP, Bates SM, Spencer FA, Arnaoutoglou E, Coppens M, Arnold DM, Caprini JA, Li M, Moffat KA, Syed S, Schulman S. Perioperative management of patients with atrial fibrillation receiving a direct oral anticoagulant. JAMA Intern Med. 2019 Aug 5;179(11):1469-1478.

  • Kearon C, de Wit K, Parpia S, Schulman S, Afilalo M, Hirsch A, Spencer FA, Sharma S, D’Aragon F, Deshaies J-F, Le Gal G, Lazo-Langner A, Wu C, Rudd-Scott L, Bates SM, Julian JA, for the PEGeD Study Investigators. Diagnosis of pulmonary embolism with D-dimer adjusted to clinical probability. N Engl J Med. 2019 Nov 28;381(22):2125-2134.

  • Walker I, Panzarella T, Couban S, Couture F, Devins G, Elemary M, Gallagher G, Kerr H, Kuruvilla J, Lee SJ, Moore J, Nevill T, Popradi G, Roy J, Schultz KR, Szwajcer D, Toze C, Foley R; Cell Therapy Transplant Canada. Addition of anti-thymocyte globulin to standard graft-versus-host disease prophylaxis versus standard treatment alone in patients with haematological malignancies undergoing transplantation from unrelated donors: final analysis of a randomised, open-label, multicentre, phase 3 trial. Lancet Haematol. 2020 Feb;7(2):e100-e111.

  • Weitz JI, Bauersachs R, Becker B, Berkowitz SD, Freitas MCS, Lassen MR, Metzig C, Raskob GE. Effect of osocimab in preventing venous thromboembolism among patients undergoing knee arthroplasty: the FOXTROT randomized clinical trial. JAMA. 2020 Jan 14;323(2):130-139. 

Clinical Protocols (and Reversals)


The information provided in the section below, such as text, graphics, and images, is for informational purposes only. It is not to be construed as medical care or medical advice and is not a replacement for medical care given by physicians or trained medical personnel. Always seek the advice of your physician or another qualified healthcare provider(s) when experiencing symptoms or health problems, or before starting any new treatment. McMaster University is not to be held responsible for any inaccuracies, omissions, or editorial errors, or any consequences resulting from the information provided.

It is your responsibility to evaluate the information and results from the tools we provide. If you are a health care professional, you should exercise your professional judgment in evaluating any information, and we encourage you to confirm the information contained on our website with other sources before undertaking any treatment or action based on it.

By continuing to view this site, visitors indicate acceptance of these terms. Visitors who do not accept these terms should not access, use, interact with or view these web pages.

Expandable List

Apixaban (Eliquis®) – On formulary as an alternative to warfarin in patients with atrial fibrillation, and for deep vein thrombosis or pulmonary embolism. Apixaban is contraindicated in patients with mechanical heart valves.

Apixaban crosses the placenta and should not be used in pregnancy. Apixaban should be avoided in nursing mothers, as it is uncertain whether it appears in breast milk.

Apixaban is not recommended in those with CrCl <15 mL/min and in those undergoing dialysis. Apixaban should be avoided in patients with severe hepatic impairment (Child-Pugh class C).

Note: Before initiating therapy, prescribers should ensure that patients have drug coverage or can pay for drugs on discharge.


Guidelines for Management of Patients on Apixaban (Eliquis®)


Conversion to or from parenteral anticoagulants
For patients currently taking apixaban, wait 12 hours after the last dose before administering a parenteral anticoagulant in therapeutic doses.

For patients currently receiving therapeutic doses of a parenteral anticoagulant, start apixaban at the time of discontinuation of a continuous intravenous infusion of heparin or substitute apixaban for the next dose of low-molecular-weight heparin (LMWH) or fondaparinux. In patients receiving prophylactic heparin, LMWH or fondaparinux, apixaban can be started 6 or more hours after the last prophylactic dose.

Conversion to or from warfarin
When converting from apixaban to warfarin, give warfarin for 2 days and then start monitoring the INR daily just before apixaban dosing.  Stop apixaban when the INR is 2.0 or higher.
When converting patients from warfarin to apixaban, discontinue warfarin and start apixaban when the INR is 2.0 or lower.

Conversion to or from dabigatran, rivaroxaban or edoxaban
When converting from apixaban to dabigatran, rivaroxaban or edoxaban, discontinue apixaban and start dabigatran, rivaroxaban (with food) or edoxaban at the time of the next planned dose of apixaban.
When converting patients from dabigatran, rivaroxaban or edoxaban to apixaban, discontinue dabigatran, rivaroxaban or edoxaban and start apixaban at the time of the next planned dose of dabigatran, rivaroxaban or edoxaban.

Administration
Drug interactions – see Table. Apixaban at the 2.5 mg dose should also be avoided in combination with clarithromycin or erythromycin.

Management of Bleeding

There is no specific antidote for apixaban.
In the event of hemorrhagic complications:

  • Discontinue treatment with apixaban and other antithrombotic drugs (e.g., ASA).
  • Initiate appropriate clinical support, e.g., surgical or local hemostasis, transfusion of red cells, volume replacement with colloid or crystalloid.
  • Consider the administration of platelet concentrations if there is thrombocytopenia or the patient is taking long-acting antiplatelet drugs (e.g., clopidogrel).
  • Consider evaluating the anticoagulant effect of apixaban by measuring the prothrombin time/international normalized ratio (PT/INR) and activated partial thromboplastin time (aPTT).  Apixaban has a greater effect on the PT/INR than on the aPTT, but neither test is affected to a great extent by apixaban.
  • Determine the creatinine and calculate the creatinine clearance using the Cockcroft
  • Gault equation because apixaban is partially excreted via the kidneys.
    Investigate the source of bleeding.

There is experimental evidence that unactivated (Octaplex or Beriplex) or activated prothrombin complex (FEIBA) concentrates or activated factor VII (Novoseven) will reverse the anticoagulant effects of apixaban.  The capacity to attenuate bleeding has only been established clinically in uncontrolled cohort studies. As a first choice in acute major bleeding, PCC 2000 units, infused over 20-30 minutes is suggested. The physician on call for Thrombosis Service MUST approve the order, except in the case of intracranial bleeding or major bleeding with trauma, when prior approval is not required.

In the event of need for emergency surgery or invasive procedure, even in a non-bleeding patient, an infusion of PCC 2000 units over 20-30 minutes is suggested when the following criteria are met:

  • Last dose of apixaban within 12 h (longer in case of severe renal impairment),
  • AND with surgery/procedure that cannot be postponed at least 8 h,
  • AND with surgery/procedure that requires normal hemostasis

The physician on call for the Thrombosis Service MUST approve this order.

Discontinuation before surgery or interventions
For most elective surgeries or interventions, apixaban should be stopped prior to surgery based on a calculated creatinine clearance and the bleeding risk associated with the procedure. If the bleeding risk is moderate, apixaban should be stopped for at least 24 h (i.e., at least 2 doses must be withheld) prior to the procedure.  If the bleeding risk is high, apixaban should be stopped for 48 to 72 h prior to the procedure.

Types of surgery associated with a high risk of bleeding include cardiac surgery, neurosurgery, abdominal surgery, urological surgery or those involving a major organ. Other procedures, such as spinal anesthesia, may also require complete absence of an apixaban effect. Other important determinants of bleeding risk include advancing age, co-morbidities (e.g. major cardiac, respiratory or liver disease) and concomitant use of antiplatelet therapy.

Table. Drug interactions with at least 50% change in the exposure to apixaban. 

Mechanism Apixaban 
Interacting drug   exposure
P-gp and CYP3A4 inhibition Ketoconazole, itraconazole, voriconazole, posaconazole  +100%
Ritonavir and other HIV protease inhibitors  +50-60%
P-gp and CYP3A4 induction Rifampicin  -54%
Carbamazepine, phenytoin, phenobarbital  -54%
St. John’s Wort  Not determined

The use of apixaban is contraindicated in patients receiving concomitant systemic treatment with strong inhibitors of both CYP 3A4 and P-gp, such as azole-antimycotics (e.g., ketoconazole, itraconazole, voriconazole, or posaconazole) and HIV protease inhibitors (e.g., ritonavir).

The concomitant use of apixaban with other strong inducers of both CYP 3A4 and P-gp (e.g., phenytoin, carbamazepine, phenobarbital or St. John’s Wort) may also lead to reduced apixaban plasma concentrations and should generally be avoided.

Reference: Eliquis® product monograph 2018 (PDF).

Reviewed/revised: April 12, 2018

1 vial = 2.5 mL
Dilute in NS or D5W or Ringer’s lactate
Use 1 vial/250 mL diluent bag or 2 vials/500 mL diluent bag (final concentration 1 mg/mL)

Dosing Checklist

  • Heparin must be discontinued before administration of Argatroban.
  • A baseline aPTT should be obtained before initiating Argatroban therapy. Argatroban is not a good choice in patients with elevated baseline aPTTs and other agents should be considered in this setting.
  • The aPTT should be rechecked 2 hours after infusion initiation and the dose should be adjusted by 0.2 – 0.5 µg/kg/min until target steady-state aPTT values of 1.5 to 3.0 times baseline are attained (not to exceed 100 seconds; maximum dose 10 µg/kg/min).
  • Monitor the INR daily when converting from Argatroban to warfarin.


Recommended Dosing Regimen for HIT Patients

If renal impairment If moderate hepatic impairment or bleeding risks 
Approved initiation dose 2 µg/kg/min; however, many centres start at 1 µg/kg/min as supratherapeutic aPTTs are common with the higher dose* No dosage adjustment Initiate at 0.5 µg/kg/min
Titrate until steady-state aPTT is 1.5 – 3.0 x baseline value (consider aiming for lower end of range if no thrombosis). Total dose not to exceed 10 µg/kg/min or aPTT of 100 seconds.
 *2008 ACCP guidelines also recommend 0.5 to 1.2 µg/kg/min for patients with heart failure, anasarca, multisystem failure, or post cardiac surgery.


Standard Starting Infusion Rates for 1 mg/mL final concentration

2.0 µg/kg/min Dose 1.0 µg/kg/min Dose
 Body Weight (kg) Infusion Rate (mL/hr)  Body Weight (kg)  Infusion Rate (mL/hr)
50 6 50 3
60 7 60 4
70 8 70 4
80 10 80 5
90 11 90 5
100 12  100 6
110 13  110 6
120 14  120 7
130 16  130 8
140 17  140 8


Conversion to Oral Anticoagulant Therapy

Initiating Oral Anticoagulant (Warfarin) Therapy
When converting to oral vitamin K antagonist therapy, a loading dose of warfarin should not be used; initiate therapy using the expected daily dose of warfarin. Due to risk of warfarin-induced microthrombosis in acute HIT, warfarin therapy should not be started pending substantial resolution of HIT (platelet count >150,000 × 109/L).

Co-Administration of Warfarin and Argatroban at Doses up to 2 µg/kg/min
The concomitant use of Argatroban with warfarin results in prolongation of INR beyond that produced by warfarin alone. INR should be measured daily while Argatroban and warfarin are co-administered. In general, with doses of Argatroban up to 2 µg/kg/min, Argatroban can be discontinued when the INR is > 4.0. After Argatroban is discontinued, repeat the INR measurement in 4 to 6 hours. If the repeat INR is below the desired therapeutic range, resume the infusion Argatroban and repeat the procedure daily until the desired therapeutic range on warfarin alone is reached.

Co-Administration of Warfarin and Argatroban at Doses greater than 2 µg/kg/min
For doses greater than 2 µg/kg/min, the relationship between INR on warfarin alone and warfarin plus Argatroban is less predictable. In this case, in order to predict the INR on warfarin alone, temporarily reduce the dose of Argatroban to a dose of 2 µg/kg/min. Repeat the INR on Argatroban and warfarin 4 to 6 hours after Argatroban reduction and follow the process outlined above for dosing Argatroban at up to 2 µg/kg/min.

*If stopping argatroban to measure the true INR while transitioning to warfarin is not an option, Factor Xa levels can be measured and the warfarin dose adjusted to achieve a therapeutic level of less than 25%.

Blood transfusions can confer clinical benefit, but can also carry serious potential risks.  All blood transfusions must be given with informed consent.  Physicians must consider the risks and benefits when they order blood, and explain the trade-offs clearly to their patients.

Information on potential risks of blood and blood products in Canada (BROKEN LINK), as well as the key elements of informed consent.

Provincial information on the evidence based use of blood, including the clinical indications for blood use.

Safe transfusion practice involves giving the right blood product to the right patient in the right way, for the right reason.  Provincial guidance on how to give blood products safely and effectively.

This information was last updated in May 2017, and approved by HRLMP Transfusion Medicine Professional Staff.

Dabigatran (Pradaxa®) – On formulary as an alternative to warfarin in patients with atrial fibrillation. Dabigatran is contraindicated in patients with mechanical heart valves.

Dabigatran crosses the placenta and should not be used in pregnancy. Dabigatran should be avoided in nursing mothers, as it is uncertain whether it appears in breast milk.

Dabigatran is contraindicated in patients with CrCl <30 mL/min.  Dose modification is not needed in patients with hepatic impairment but dabigatran should be used with caution in those with cirrhosis or baseline coagulopathy who are at high risk of bleeding.

Note: Prior to initiating therapy, prescribers should ensure that patients have drug coverage or are able to pay for drug on discharge.

Guidelines for Management of Patients on Dabigatran (Pradax®)

 

Conversion to or from parenteral anticoagulants
For patients currently taking dabigatran, wait 12 hours (CrCl ?30 mL/min) or 24 hours (CrCl <30 mL/min) after the last dose of dabigatran before initiating treatment with a parenteral anticoagulant.

For patients currently receiving therapeutic doses of a parenteral anticoagulant, start dabigatran 0 to 2 hours before the time of discontinuation of a continuous intravenous infusion of heparin or substitute dabigatran for the next dose of low-molecular-weight heparin (LMWH) or fondaparinux. In patients receiving prophylactic heparin, LMWH or fondaparinux, daigatran can be started 6 or more hours after the last prophylactic dose.

Conversion to or from warfarin
When converting from dabigatran to warfarin, adjust the starting time of warfarin based on creatinine clearance as follows:

  • For CrCl >50 mL/min, start warfarin 3 days before discontinuing dabigatran.
  • For CrCl 31-50 mL/min, start warfarin 2 days before discontinuing dabigatran.
  • For CrCl 15-30 mL/min, start warfarin 1 day before discontinuing dabigatran.
  • For CrCl <15 mL/min, no recommendations can be made – consult with Thrombosis Service.

Because dabigatran can contribute to an elevated INR, the INR will better reflect warfarin’s effect after dabigatran has been stopped for at least 2.0 days.

When converting patients from warfarin therapy to dabigatran, discontinue warfarin and start dabigatran when the international normalized ratio (INR) is below 2.3.

Conversion to or from rivaroxaban, apixaban or edoxaban
When converting from dabigatran to rivaroxaban, apixaban or edoxaban, discontinue dabigatran and start rivaroxaban (with food), apixaban or edoxaban at the time of the next planned dose of dabigatran.

When converting patients from rivaroxaban, apixaban or edoxaban to dabigatran, discontinue rivaroxaban, apixaban or edoxaban and start dabigatran at the time of the next planned dose of rivaroxaban or apixaban.

Administration
Dabigatran is preferably given with food to minimize the risk of dyspeptic side effects. Dabigatran capsules should be swallowed whole. The capsule should not be crushed, chewed or opened before swallowing. Capsules should be stored in their blister package or in the original bottle from the manufacturer to protect them from moisture.

Drug interactions – see Table.

Dabigatran should be taken 2 h before verapamil, quinidine or antacids.

Management of Bleeding
There is an antidote to dabigatran, idarucizumab or Praxbind®. In most situations, however, bleeding can be managed without the antidote.

In the event of hemorrhagic complications:
• Discontinue treatment with dabigatran and other antithrombotic drugs (e.g., ASA)
Initiate appropriate clinical support, e.g. surgical or local hemostasis, transfusion of red cells, volume substitution, inotropic drugs.
• Consider administration of platelet concentrates in cases where thrombocytopenia is present or long-acting antiplatelet drugs (e.g., clopidogrel) have been used.
• Consider evaluating the anticoagulant effect of dabigatran by measuring the prothrombin time/international normalized ratio (PT/INR) and activated partial thromboplastin time (aPTT).  Dabigatran has a variable effect on the PT/INR and a non-linear effect on the aPTT. Measurement of aPTT may help guide therapy to the extent that therapeutic levels of dabigatran will cause a prolongation. The thrombin clotting time (TCT) is very sensitive and is always prolonged in the presence of any dabigatran. The dilute TCT (Hemoclot® assay) shows a linear response with dabigatran plasma concentration. This test requires a hematologist’s approval and is not performed as a “stat” assay.
• Determine the creatinine and calculate the creatinine clearance using the Cockcroft Gault equation because dabigatran is mostly excreted via the kidneys.
• Investigate the source of bleeding.
• For life-threatening bleeding, bleeding in a closed space (e.g. intracranial, intraspinal, muscle hematoma with compartment syndrome), or ongoing bleeding despite supportive measures, administer idarucizumab 5 g intravenously.

In the event of need for emergency surgery or invasive procedure, even in a non-bleeding patient, administer idarucizumab 5 g intravenously if the following criteria are met:

  • Last dose of dabigatran within 12 h (longer in case of moderate-severe renal impairment),
  • AND with surgery/procedure that cannot be postponed at least 8 h,
  • AND with  surgery/procedure that requires normal hemostasis

Consult with physician on call for the Thrombosis Service if there is no improvement and always when a second dose of idarucizumab is being considered.
Dabigatran is primarily excreted in the urine; therefore, maintain adequate diuresis. Dabigatran can be dialyzed (protein binding is low) and it may take 6-8 hours to clear dabigatran this way; however, data supporting this approach are limited and dialysis is rarely needed if idarucizumab is administered. The duration of dialysis may be best guided by normalization of aPTT and/or shortening of the 2 U TCT to 60 s.

Discontinuation before surgery
For most elective surgeries or interventions, dabigatran should be stopped prior to surgery based on a calculated creatinine clearance and the bleeding risk associated with the procedure.

Renal function
(CLCR, mL/min)
 

Half-life (hours)a  

Timing of discontinuation after last dose of dabigatran before surgery 
 Standard risk of bleeding High risk of bleedingb 
>80 13 (11-22)  24 hours 2-4 days
 >50 to <80 15 (12-34)  24 hours 2-4 days
 >30 to <50 18 (13-23)  at least 2 days (48 hours) 4 days
<30c 27 (22-35)  4-5 days  >5 days
  1. Data from renal impairment study in healthy volunteers, geometric mean (range).
  2. Types of surgery associated with a high risk of bleeding include but are not limited to cardiac surgery, neurosurgery, abdominal surgery, urological surgery or those involving a major organ. Other procedures such as spinal anesthesia may also require complete absence of a dabigatran effect. Other important determinants of bleeding risk include advancing age, co-morbidities (e.g. major cardiac, respiratory or liver disease) and concomitant use of antiplatelet therapy.
  3. Dabigatran etexilate is contraindicated for use in these patients. CrCl = creatinine clearance.

Table. Drug interactions with at least 50% change in the exposure to dabigatran

Mechanism Dabigatran
 Interacting drug exposure
 P-gp inhibition Ketoconazole, itraconazole +140%
Ritonavir and other HIV protease inhibitors +60-150%
Dronedarone +70-100%
 P-gp induction Rifampicin -67%
Carbamazepine, phenytoin, phenobarbital -60-70%
St. John’s Wort Not determined

The use of dabigatran is contraindicated in patients receiving concomitant systemic treatment with strong P-gp inbitors, such azole–antimycotics (e.g., ketoconazole or itraconazole), HIV protease inhibitors (e.g., ritonavir), and dronedarone.

The concomitant use of dabigatran with strong P-gp inducers (e.g. rifampin, carbamazepine, phenytoin, phenobarbital or St. John’s Wort) may lead to reduced dabigatran plasma concentations and should be generally avoided.

References
Stangier J, Rathgen K, Stähle H, et al. Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate. Clin Pharmacokinet 2010; 49: 259–268.
Pradaxa® product monograph 2020 (PDF)
PraxBind® product monograph 2020 (PDF)

Reviewed/revised: April 12, 2018

Each 0.6 mL ampule of danaparoid contains 750 anti-Xa units.

Loading Dose
2,250 U IV bolus*, followed by 400 U/hour x 4 hours, then 300 U/hour x 4 hours, then use maintenance dose IV, as below.
*Adjust bolus dose for body weight:

<60 kg  1500 U (2 ampules)
 60-75 kg  2250 U (3 ampules)
 75-90 kg  3000 U (4 ampules)
 >90 kg  3750 U (5 ampules)

Maintenance (IV)
200 U/hour*, with subsequent dose adjustments (bolus adjustments if desired can be given in 50 cc minibags of D5W, NS or Ringer’s Lactate) made using anti-Xa levels (target range 0.5-0.8 anti-Xa U/mL, if available.

Prepare danaparoid for intravenous infusion as follows: add 3 ampules (2250 U) danaparoid to 250 mL D5W or NS or Ringer’s Lactate (ie. 9 anti-Xa U/mL), and infuse at 44 mL/hr (=396 U/hr) x4 hours, then 33 mL/hr (=297 U/hr) x 4 hours, then 22 mL/hr (198 U/mL).

The half-life of anti-Xa activity is approximately 25 hours; when overlapping danaparoid therapy with initiation of warfarin anticoagulation, the physician should consider discontinuing the danaparoid when the INR begins to increase on warfarin.

Maintenance (SC)
After initial IV therapy
2250 U subcutaneously bid*
*Adjust does for body weight

<55 kg  1500 U subcutaneously bid
 >90 kg  1750 U subcutaneously tid

Prophylaxis

90 kg or less 750 U subcutaneously bid
 > 90 kg 1250 U subcutaneously bid

Prothrombin Complex Concentrate (PCC) is available through Canadian Blood Services. Two PCCs are currently available, Octaplex and Beriplex; each contains factor II, VII, IX, X, Protein C, Protein S, and small quantities of heparin.

Content
(unit in 500 U of concentrate) 
Octaplex®
from Octapharma
Beriplex®
from CSL Behring
 Factor II (IU) 260-760 380-800
 Factor VII (IU) 180-480 200-500
 Factor IX (IU) 400-620 400-620
 Factor X (IU) 360-600 500-1020
 Protein C (IU) 140-620 420-820
 Protein S (IU) 140-640  240-680
 Heparin (IU)  80-310  8-40
 Other components Sodium citrate Human antithrombin, human albumin, sodium citrate

Indications
PCC is indicated for treatment of severe or life-threatening acute bleeding associated with warfarin (Coumadin®) OR for rapid reversal of warfarin for urgent surgical procedures in less than 6 hours.
PCC has also been used for treatment of severe or life-threatening acute bleeding associated with factor Xa inhibitors: apixaban (Eliquis®), rivaroxaban (Xarelto®) or edoxaban (Lixiana®)

Order must be approved by the physician on call for the Thrombosis Service except in cases of intracranial hemorrhage or major bleed with trauma (to expedite product release).

Dosage
Warfarin Reversal

Dosing for target INR ~ 1.5

INR = 2-3 20 IU/kg
INR = 3-6 30 IU/kg
INR > 6  40 IU/kg

*    Add 10 IU/kg for target INR < 1.2
*    Also give vitamin K 5-10 mg IV over 30 minutes.
*    Under normal circumstances the dose should not exceed 3000 IU with a maximum infusion speed of 8mL/min.
*    For severe acute bleed with unknown INR, give 2000 IU.

Factor Xa Inhibitor Reversal
Give PCC 2000 IU.

Supplied
Human product supplied as a lyophilized powder with 20 mL diluent for reconstitution.
Each vial is approximately 500 IU
Each vial contains a range of factor activity eg. Factor IX -400-620 IU

Relative Contraindications
Patients with heparin-induced thrombocytopenia (HIT) or suspected HIT (product contains heparin).

Theodore E. Warkentin MD, BSc (Med), FRCPC, FACP
Regional Director, Transfusion Medicine
Hamilton Regional Laboratory Medicine Program
Hematologist, Service of Clinical Hematology

Sam Schulman MD
Professor of Medicine
Thrombosis Service, McMaster Clinic & HHS – General Hospital

Reviewed/revised: April 12, 2018

Rivaroxaban (Xarelto®) – On formulary as an alternative to warfarin in patients with atrial fibrillation, deep vein thrombosis or pulmonary embolism, and for thromboprophylaxis after elective hip or knee arthroplasty. Rivaroxaban is contraindicated in patients with mechanical heart valves.

Rivaroxaban crosses the placenta and should not be used in pregnancy. It has been shown that rivaroxaban appears in breast milk; therefore, this drug should also be avoided in nursing mothers.

There is limited information on rivaroxaban in patients with CrCl <30 mL/min and in those with moderate or severe hepatic impairment (Child-Pugh class B or C). Rivaroxaban should be avoided in such patients.

Note: Prior to initiating therapy, prescribers should ensure that patients have drug coverage or are able to pay for drug on discharge.

Guidelines for Management of Patients on Rivaroxaban (Xarelto®)

Conversion to or from parenteral anticoagulants
For patients currently taking rivaroxaban, wait 24 hours after the last dose before administering a parenteral anticoagulant in therapeutic doses.

For patients currently receiving therapeutic doses of a parenteral anticoagulant, start rivaroxaban at the time of discontinuation of a continuous intravenous infusion of heparin or substitute rivaroxaban for the next dose of low-molecular-weight heparin (LMWH) or fondaparinux. In patients receiving prophylactic heparin, LMWH or fondaparinux, rivaroxaban can be started 6 or more hours after the last prophylactic dose.

Conversion to or from warfarin

When converting from rivaroxaban to warfarin, give warfarin for 2 days and then start monitoring the INR daily, just prior to rivaroxaban dosing.  Stop rivaroxaban when the INR is 2.0 or higher.

When converting patients from warfarin to rivaroxaban, discontinue warfarin and start rivaroxaban when the INR is 2.5 or lower.

Conversion to or from dabigatran, apixaban or edoxaban
When converting from rivaroxaban to dabigatran, apixaban or edoxaban, discontinue rivaroxaban and start dabigatran, apixaban or edoxaban at the time of the next planned dose of rivaroxaban.

When converting patients from dabigatran, apixaban or edoxaban to rivaroxaban, discontinue dabigatran, apixaban or edoxaban and start rivaroxaban at the time of the next planned dose of dabigatran, apixaban or edoxaban.

Administration
When given at doses above 10 mg, rivaroxaban should be given with food for optimal absorption.

Drug interactions – see Table

Management of Bleeding
There is no specific antidote for rivaroxaban.

In the event of hemorrhagic complications:
• Discontinue treatment with rivaroxaban and other antithrombotic drugs (e.g., ASA).
• Initiate appropriate clinical support, e.g., surgical or local hemostasis, transfusion of red cells, volume replacement with colloid or crystalloid.
• Consider administration of platelet concentrates if there is thrombocytopenia or the patient is taking long-acting antiplatelet drugs (e.g., clopidogrel).
• Consider evaluating the anticoagulant effect of rivaroxaban by measuring the prothrombin time/international normalized ratio (PT/INR) and activated partial thromboplastin time (aPTT).  Rivaroxaban has a greater effect on the PT/INR than on the aPTT.
• Determine the creatinine and calculate the creatinine clearance using the Cockcroft Gault equation because rivaroxaban is partially excreted via the kidneys.
• Investigate the source of bleeding.

There is experimental evidence that unactivated (Octaplex or Beriplex) or activated prothrombin complex (FEIBA) concentrates or activated factor VII (Novoseven) will reverse the anticoagulant effects of rivaroxaban.  The capacity to attenuate bleeding has only been established clinically in uncontrolled cohort studies. As a first choice in acute major bleeding, PCC 2000 units, infused over 20-30 minutes is suggested. The physician on call for Thrombosis Service MUST approve the order, except , however, not required in case of intracranial bleeding or major bleed with trauma, when prior approval is not required.

In the event of need for emergency surgery or invasive procedure associated with a high risk of bleeding, even in a non-bleeding patient, an infusion of PCC 2000 units, over 20-30 minutes is suggested when the following criteria are met:

• Last dose of rivaroxaban within 24 h (longer in case of severe renal impairment),
• AND with surgery/procedure that cannot be postponed for at least 8 h,
• AND with surgery/procedure that requires normal hemostasis

The physician on call for the Thrombosis Service MUST approve this order.

Discontinuation before surgery or interventions
For most elective surgeries or interventions, rivaroxaban should be stopped prior to surgery based on a calculated creatinine clearance and the bleeding risk associated with the procedure. If the bleeding risk is moderate, rivaroxaban should be stopped for at least 24 h prior to the procedure.  If the bleeding risk is high, rivaroxaban should be stopped for 48 to 72 h prior to the procedure.

Types of surgery associated with a high risk of bleeding include cardiac surgery, neurosurgery, abdominal surgery, urological surgery or those involving a major organ. Other procedures, such as spinal anesthesia, may also require complete absence of a rivaroxaban effect. Other important determinants of bleeding risk include advancing age, co-morbidities (e.g. major cardiac, respiratory or liver disease) and concomitant use of antiplatelet therapy.

A normal anti-Xa rivaroxaban level indicates absence of rivaroxaban anticoagulant activity; however, routine checking of rivaroxaban levels prior to surgery is not recommended or required. The anti-Xa rivaroxaban level is a non-stat test and is available only with a hematologist’s approval.

Table. Drug interactions with at least 50% change in the exposure to rivaroxaban.

Mechanism Rivaroxaban
Interacting drug  exposure
 P-gp and CYP3A4 inhibition Ketoconazole, itraconazole, voriconazole, posaconazole  +160%
Ritonavir and other HIV protease inhibitors  +153%
 P-gp and CYP3A4 induction  Rifampicin  -50%
 Carbamazepine, phenytoin, phenobarbital  -50%
 St. John’s Wort  Not determined

The use of rivaroxaban is contraindicated in patients receiving concomitant systemic treatment with strong inhibitors of both CYP 3A4 and P-gp such as azole-antimycotics (e.g., ketoconazole, itraconazole, voriconazole or posaconazole) and HIV protease inhibitors (e.g., ritonavir).

The concomitant use of rivaroxaban with other strong inducers of both CYP 3A4 and P-gp (e.g., phenytoin, carbamazepine, phenobarbital or St. John’s Wort) may also lead to reduced rivaroxaban plasma concentrations and should generally be avoided.

Reference: Xarelto® product monograph 2019 (PDF).

Reviewed/revised: April 12, 2018

Our Research in the News

McMaster Health Sciences sign
Book Icon
Dr. Verdu
Two researchers working in a lab setting using micropipettes

McMaster scoops up $20M more for COVID-19 research

Hematology & Thromboembolism Research